ArticleDiscover oncology2025
CCL20 mediates the effect of cathepsin S on hepatocellular carcinoma development insights from Mendelian randomization and bioinformatics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDysregulation of cathepsins is associated with cancer development and progression. However, their specific role in hepatocellular carcinoma (HCC) remains unclear.
methodsWe employed two-sample Mendelian randomization (MR) analyses to investigate potential causal relationships between cathepsins, 91 circulating inflammatory cytokines (CICs), and HCC. Subsequently, we explored causal associations between identified cathepsins and carcinogenic CICs. Finally, using the GSE14520 dataset, we conducted comprehensive bioinformatics analyses on the encoding genes of the screened cathepsins and CICs.
resultsInverse-variance weighted (IVW) MR revealed that the genetically predicted Cathepsin S (CTSS) and seven CICs, including C-C motif chemokine 20 (CCL20), Fibroblast growth factor 19, Interleukin-1-alpha, Interleukin-20 receptor subunit alpha, Interleukin-24, Monocyte chemoattractant protein-3 and Stem cell factor levels, were intrinsically associated with increased HCC risk. Additionally, a casual estimate from Cathepsin S to CCL20 was identified. Sensitivity analysis found little evidence of heterogeneity and horizontal pleiotropy. CTSS and CCL20 gene expression was significantly dysregulated between HCC and adjacent normal liver tissue, exhibiting a positive correlation. Based on CTSS and CCL20 expression levels, we stratified the GSE14520 set into four clusters. Notably, the CTSShiCCL20low subgroup carried the most dismal overall survival, which was further validated in the GSE76427 and International Cancer Genome Consortium (ICGC) datasets. This subgroup also exhibited relatively lower predicted half-maximal inhibitory concentrations (IC50s) of multiple chemo- and targeted-therapies. Moreover, significant differences among the four clusters were observed in the stromal and immune score, immunocyte infiltration levels, especially Macrophages M1, Monocytes, Mast cell resting and Dendritic cells activated.
conclusionsOur exploratory analyses suggest that CCL20 may mediate the effect of CTSS on HCC development. Patients with CTSShighCCL20low HCC tumors may have a poorer prognosis but could be more susceptible to certain chemotherapeutic and targeted drugs. However, further in vivo and in vitro are required to elucidate the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.